The Effects of Linezolid and Vancomycin on Inflammation and Cellular Signaling Vents

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00811980

Enrollment

Registered

2008-12-19

Start date

2009-01-31

Completion date

2010-06-30

Last updated

2011-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Brief summary

We will determine if linezolid inhibits cellular activation and production of pro-inflammatory cytokines, providing mechanistic rationale for its clinical efficacy and the justification for further investigations in S. Aureus sepsis.

Interventions

DRUGLinezolid or Vancomycin

Whole blood samples from healthy subjects will be incubated with MRSA bacterium or bacterial toxins in the presence and absence of either linezolid or vancomycin. Final concentrations will mimic physiologic conditions. Platelets and leukocytes will be isolated and assayed for the presence of absence of activation and pre-mRNA splicing.

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Healthy, taking no medications, and not recently hospitalized

Exclusion criteria

* Infection (active)

Design outcomes

Primary

Measure	Time frame	Description
IL-6	12 Months	Measurement of IL-6 release in response to MRSA.

Secondary

Measure	Time frame	Description
MCP-1	12 Months	Measurement of MCP-1 release in response to MRSA.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026